Peanut

DBV Technologies progresses with Viaskin patch for peanut and milk allergies, aiming for FDA approval. Studies show promising results, with 81% of toddlers tolerating peanuts after 2 years. The patch, part of epicutaneous immunotherapy, may offer sustained unresponsiveness. DBV plans to expand treatment to cashew and potentially other allergens.

IgGenix announced the first patient dosed with IGNX001, a monoclonal antibody therapeutic for peanut allergy, in the ACCELERATE Peanut phase 1 clinical trial. The trial aims to assess safety, tolerability, and proof of mechanism in patients aged 15 years and older. IGNX001 attaches to peanut proteins to neutralize them, differing from other immunotherapies like Palforzia and Xolair. The trial is ongoing in Australia, with recruitment targeting older adolescents and adults, and initial results expected mid-2025.

Families of children with food allergies face constant vigilance and emotional burden due to the lack of a cure. FDA-approved treatments like oral immunotherapy for peanut allergy and injectable medication for multiple food allergies reduce worry about accidental ingestion but do not allow carefree eating. Ongoing clinical trials at Lurie Children's Hospital explore innovative therapies, including a peanut patch and a dissolvable tablet under the tongue, aiming to minimize severe reactions and offer families peace of mind.

The article reviews U.S. food allergy guidelines, prevalence, and management, highlighting racial disparities, economic impacts, and advancements in treatment, including immunotherapy and FDA-approved drugs for peanut allergy.

DBV Technologies announced positive Phase 3 EPITOPE trial results for Viaskin Peanut in peanut-allergic toddlers, showing 67.0% of treated subjects met response criteria vs. 33.5% in placebo. The trial met its primary endpoint with a significant treatment effect (p<0.001) and consistent safety profile. DBV plans further analysis and regulatory exploration for children ages 1 to 3.